Hepion Pharmaceuticals, Inc. HEPA

HEPA Company Overview

Hepion Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapeutic treatments for chronic liver disease, hepatocellular carcinoma (HCC), and related fibrotic and inflammatory conditions. The company’s primary research efforts have centered on cyclophilin inhibition technology, particularly its lead drug candidate, Rencofilstat, which has been evaluated for the treatment of non-alcoholic steatohepatitis (NASH), liver fibrosis, and liver cancer. Hepion has operated within the biotechnology and pharmaceutical development industries, with revenue historically derived primarily from financing activities rather than commercial product sales, as the company has remained in the clinical development stage.

The company evolved from earlier biotechnology operations and adopted the Hepion Pharmaceuticals name after strategic restructuring and licensing activities focused on liver disease therapeutics. Its positioning has been tied to its proprietary cyclophilin inhibitor platform, which management has stated may address multiple pathways associated with fibrosis, inflammation, and viral disease progression. Public filings and investor materials indicate that Hepion sought differentiation through multi-target therapeutic mechanisms intended to address complex liver diseases with limited approved treatment options.